MedTech Acquisition Corporation does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.
IPO Year: 2021
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|
TriSalus Life Sciences®, Inc. ("TriSalus" or the "Company"), an oncology company in the process of going public through a business combination transaction (the "Business Combination") with MedTech Acquisition Corporation (NASDAQ:MTAC) ("MedTech" or "MTAC"), today announced that James "Jim" Alecxih has joined the Company in the newly created role of President, Device Technology Business. Mr. Alecxih brings to TriSalus more than 30 years of experience in product development, launch and marketing strategies. His responsibilities will include overseeing the growth and development of TriSalus' TriNav® Infusion System ("TriNav®"), including device engineering, device quality, sales, marketing, a
4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
424B3 - TriSalus Life Sciences, Inc. (0001826667) (Filer)
424B3 - TriSalus Life Sciences, Inc. (0001826667) (Filer)
8-K - TriSalus Life Sciences, Inc. (0001826667) (Filer)
8-K - TriSalus Life Sciences, Inc. (0001826667) (Filer)
EFFECT - TriSalus Life Sciences, Inc. (0001826667) (Filer)
EFFECT - TriSalus Life Sciences, Inc. (0001826667) (Filer)
424B3 - TriSalus Life Sciences, Inc. (0001826667) (Filer)
424B3 - TriSalus Life Sciences, Inc. (0001826667) (Filer)
S-1 - TriSalus Life Sciences, Inc. (0001826667) (Filer)
S-1/A - TriSalus Life Sciences, Inc. (0001826667) (Filer)
SC 13G - TriSalus Life Sciences, Inc. (0001826667) (Subject)
SC 13G - TriSalus Life Sciences, Inc. (0001826667) (Subject)
SC 13G - TriSalus Life Sciences, Inc. (0001826667) (Subject)
SC 13D - TriSalus Life Sciences, Inc. (0001826667) (Subject)
SC 13G - TriSalus Life Sciences, Inc. (0001826667) (Subject)
SC 13G - TriSalus Life Sciences, Inc. (0001826667) (Subject)
SC 13D - TriSalus Life Sciences, Inc. (0001826667) (Subject)
SC 13D - TriSalus Life Sciences, Inc. (0001826667) (Subject)
SC 13D/A - TriSalus Life Sciences, Inc. (0001826667) (Subject)
SC 13D/A - MedTech Acquisition Corp (0001826667) (Subject)
Advances TriSalus' Platform Focused on Improving Outcomes for Patients with Liver and Pancreatic Cancer Expected to Advance Technology Development and Sales Growth Advancing SD-101 Into Phase 2 Clinical Trial in Uveal Melanoma, Phase 1 Trial in Pancreatic Cancer and Continuing Clinical Trials in HCC and Cholangiocarcinoma Provides Cash Runway through Mid-2024 to Fund Key Milestones TriSalus' Common Stock Expected to Begin Trading on the Nasdaq under Symbol "TLSI" on August 11, 2023 TriSalus Life Sciences® Inc., (TriSalus or the Company), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors,
TriSalus Life Sciences®, Inc. (“TriSalus” or the “company”), an oncology company in the process of going public through a business combination transaction (the “Business Combination”) with MedTech Acquisition Corporation (NASDAQ:MTAC) (“MedTech” or “MTAC”), today announced that it has expanded the reach of its ongoing Pressure-Enabled Regional Immuno-Oncology™ (“PERIO™-01” and “PERIO™-02”) clinical program. In recent months TriSalus has opened five new PERIO™-01 (NCT04935229) clinical trial sites, at Stanford University Hospitals, University of California Los Angeles, University of Colorado’s Anschutz Medical Campus, University of Washington Medical Center and University of Miami’s Sylveste
TriSalus Life Sciences has identified a special purpose acquisition company (SPAC) path for its NASDAQ debut, with a deal to merge with MedTech Acquisition Corporation (NASDAQ:MTAC) The company's business is built on TriNav, an infusion system that enables the modulation of pressure and flow to overcome tumoral pressure and thereby improve the delivery of anti-cancer drugs. The pressure-enabled drug delivery (PEDD) technology was launched in 2020. In 2021, TriNav achieved $8.4 million in net sales and is on track to achieve $12.6 million in 2022. TriSalus also uses the technology in its internal drug development pipeline, led by SD-101, a toll-like receptor 9 agonist delivered by PEDD
Oncology Therapeutics Company Focused on Transforming Cancer Treatment with Proprietary Innovative Therapies and Disruptive Delivery Technology Company Has a Differentiated and Fast-growing, Commercial Drug Delivery Business; Significant Potential Upside from Immunotherapy Platform Post-transaction, Expects to be Fully Funded to Allow Key Data Read-Outs for Device and Immunotherapy Platform in Late 2024 Accelerates Access to Resources to Drive Continued Commercialization of TriNav® Infusion System and Advance SD-101 Clinical Programs Expected Cash at Closing Includes Up to $50 Million from an Anticipated Convertible Note from Leading Institutional Investor
Merger activity declined last week with three new deals announced and five deals completed. Two of the three new deals announced were potential deals in the works. I was surprised to see that four SPAC combinations were terminated. Clearly the SPAC bubble continues to deflate due to unfavorable market conditions. Things are however starting to look very interesting on the merger arbitrage front. We have identified three deals that look attractive to us and we will be writing about them in our March mid-month update for premium subscribers. When we launched Inside Arbitrage in 2018 we were tracking two strategies including merger arbitrage and insider trading. Since then we have expanded bot
Memic Innovative Surgery Ltd has pulled out of a reverse merger deal with MedTech Acquisition Corporation (NASDAQ:MTAC), a special purpose acquisition company (SPAC) focused on medical technology. Last August, Memic announced its merger with MedTech Acquisition Corporation to take the surgical robot public. As of this week, however, the deal is off. Memic is a developer of the FDA-cleared Hominis system for robotic-assisted surgery. In an announcement published Thursday, the companies said they had mutually decided to terminate their business combination, citing "market conditions and associated volatility as a result of recent world events." "With the recent adoption of our Hominis sy
Advances TriSalus' Platform Focused on Improving Outcomes for Patients with Liver and Pancreatic Cancer Expected to Advance Technology Development and Sales Growth Advancing SD-101 Into Phase 2 Clinical Trial in Uveal Melanoma, Phase 1 Trial in Pancreatic Cancer and Continuing Clinical Trials in HCC and Cholangiocarcinoma Provides Cash Runway through Mid-2024 to Fund Key Milestones TriSalus' Common Stock Expected to Begin Trading on the Nasdaq under Symbol "TLSI" on August 11, 2023 TriSalus Life Sciences® Inc., (TriSalus or the Company), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tu
MedTech Acquisition Corporation (NASDAQ:MTAC) ("MedTech" or the "Company") today announced that it convened and then adjourned, without conducting any business, its special meeting of stockholders (the "Special Meeting"). The Special Meeting is being held to vote on certain proposals related to the proposed business combination (the "Business Combination") with TriSalus Life Sciences ("TriSalus"). The Special Meeting has been adjourned until 11:00 a.m. Eastern Time on August 8, 2023. The Special Meeting will still be held virtually via webcast, and stockholders may attend and participate online by visiting https://www.cstproxy.com/medtechacquisition/sm2023. Participants will be able to li
New data from PERIO-01 clinical trial indicates PEDD™ method resulted in modulation of the tumor microenvironment and decreased circulating tumor DNA (ctDNA) levels TriSalus Life Sciences® Inc., (TriSalus or the Company), an oncology company in the process of going public through a business combination transaction (the Business Combination) with MedTech Acquisition Corporation (NASDAQ:MTAC) (MedTech or MTAC), today announced additional Phase 1 clinical data presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting taking place in Chicago, Illinois, from June 2-6, 2023. TriSalus' ongoing Phase 1 Pressure-Enabled Regional Immuno-Oncology (PERIO-01) (NCT04935229) cl
TriSalus Life Sciences® Inc., ("TriSalus" or the "Company"), an oncology company in the process of going public through a business combination transaction (the "Business Combination") with MedTech Acquisition Corporation (NASDAQ:MTAC) ("MedTech" or "MTAC"), today announced new Phase 1 clinical data presented at the American Association for Cancer Research ("AACR") 2023 Annual Meeting taking place in Orlando, Florida, from April 14-19, 2023. The clinical data presented at the AACR 2023 Annual Meeting relates to the Company's ongoing Pressure-Enabled Regional Immuno-Oncology ("PERIO-01") clinical study for uveal melanoma with liver metastases ("UMLM"). The PERIO-01 trial is studying an inve
TriSalus Life Sciences®, Inc. ("TriSalus" or the "Company"), an oncology company in the process of going public through a business combination transaction (the "Business Combination") with MedTech Acquisition Corporation (NASDAQ:MTAC) ("MedTech" or "MTAC"), today announced that James "Jim" Alecxih has joined the Company in the newly created role of President, Device Technology Business. Mr. Alecxih brings to TriSalus more than 30 years of experience in product development, launch and marketing strategies. His responsibilities will include overseeing the growth and development of TriSalus' TriNav® Infusion System ("TriNav®"), including device engineering, device quality, sales, marketing, a
Data Further Supports the Potential of the Company's Therapeutic Platform to Improve Immunotherapy Outcomes for Patients with Liver and Pancreatic Tumors TriSalus Life Sciences®, Inc. ("TriSalus" or the "Company"), an oncology company in the process of going public through a business combination transaction (the "Business Combination") with MedTech Acquisition Corporation (NASDAQ:MTAC) ("MedTech" or "MTAC"), today posted an updated investor presentation with new data regarding its ongoing Pressure-Enabled Regional Immuno-Oncology™ ("PERIO™-01" and "PERIO™-02") clinical studies for primary and metastatic liver tumors. The presentation is available on the investor relations section of the Co
TriSalus Life Sciences®, Inc. ("TriSalus" or the "company"), an oncology company in the process of going public through a business combination transaction (the "Business Combination") with MedTech Acquisition Corporation (NASDAQ:MTAC) ("MedTech" or "MTAC"), today announced that it has expanded the reach of its ongoing Pressure-Enabled Regional Immuno-Oncology™ ("PERIO™-01" and "PERIO™-02") clinical program. In recent months TriSalus has opened five new PERIO™-01 (NCT04935229) clinical trial sites, at Stanford University Hospitals, University of California Los Angeles, University of Colorado's Anschutz Medical Campus, University of Washington Medical Center and University of Miami's Sylvest
The Company recommends all of its stockholders to vote FOR the Extension Amendment at the upcoming Special Meeting. New York, NY, Dec. 07, 2022 (GLOBE NEWSWIRE) -- MedTech Acquisition Corporation (NASDAQ:MTAC) ("MedTech" or the "Company") today announced that on December 7, 2022, it convened and then adjourned, without conducting other business, its special meeting of stockholders (the "Special Meeting") in lieu of its 2022 Annual Meeting of Stockholders from December 7, 2022 to 11:00 a.m. Eastern Time on December 12, 2022. The Special Meeting is being adjourned in order to solicit more votes toward the approval to amend the Company's amended and restated certificate of incorporation
TriSalus Life Sciences®, Inc. ("TriSalus") (the "Company"), an oncology therapeutics company in the process of going public through a business combination transaction (the "Business Combination") with MedTech Acquisition Corporation (NASDAQ:MTAC) ("MedTech" or "MTAC"), today filed a presentation for investors with additional information regarding its ongoing Pressure-Enabled Regional Immuno-Oncology™ ("PERIO™ 01") and ("PERIO™ 02") clinical studies for primary and metastatic liver tumors. "We are commercializing our TriNav® Infusion System (TriNav®) and developing SD-101 to potentially enable more patients with liver and pancreatic tumors to benefit from immunotherapeutics and the current
TEL AVIV, Israel and FORT LAUDERDALE, Fla., March 10, 2022 (GLOBE NEWSWIRE) -- MedTech Acquisition Corporation (NASDAQ:MTAC) ("MedTech"), a publicly traded special purpose acquisition company (SPAC) focused on medical technology, and Memic Innovative Surgery Ltd. ("Memic"), a medical device company dedicated to transforming surgery with its proprietary surgical robotic technology, today announced that both companies have mutually agreed to terminate, effective immediately, their previously announced business combination agreement dated August 12, 2021 due to market conditions and associated volatility as a result of recent world events. "While we are disappointed that our proposed busines